Last checked at 
Nov 12 (Reuters) - Sarepta Therapeutics Inc saidthe U.S. Food and Drug Administration had raised concerns aboutthe trial for the company's experimental muscle disorder drugand considered the marketing application for the treatment to bepremature.
Sarepta shares fell 39 percent to $22.20 in premarket tradeon Tuesday.
The FDA said the recent trial failure of a competing drugmade by GlaxoSmithKline and Prosensa had raised"considerable doubt" about Sarepta's trial. (Reporting by Esha Dey in Bangalore; Editing by Savio D'Souza)
